Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China
ConclusionsThe health economic evaluations revealed that for Chinese patients with reflux esophagitis, vonoprazan and the CYP2C19 genotype-guided strategy were not cost-effective regimens compared with lansoprazole. However, we found that in certain conditions like a reduction in the price of vonoprazan and in patients with severe reflux esophagitis these could be cost-effective.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Acid Reflux | China Health | Clinical Trials | Drugs & Pharmacology | Gastroesophageal Reflux Disease | GERD | Lansoprazole | Prevacid